Therapeutic Options for the Treatment of Community-Acquired Pneumonia Caused by Streptococcus Pneumoniae

Abstract

Streptococcus pneumoniae is the most common cause of community acquired pneumonia, acute otitis media, meningitis and other infections, asymptomatic colonizing nasopharynx of healthy children and adults. Since late 1970s there has been a steady decline in the susceptibility of Streptococcus pneumoniae to various groups of antibiotics.The number of antibiotic-resistant pneumococcal infections has decreased due to the success of the pneumococcal conjugate vaccine. In addition to vaccination, guidelines for treatment of pneumococcal disease are developed by various professional and scientific associations, intending to slow or reverse drug-resistant pneumococcal infections. The aim of this work is to provide a generated information about therapeutic options for the treatment of community-acquired pneumonia caused by Streptococcus pneumoniae, based on the recommendations and statements from various guidelines developed by different proffesional and scientific associations but limited on drugs available on the market in Bosnia and Herzegovina.